Influenza nucleoprotein: Promising target for antiviral chemotherapy

Antiviral Chemistry and Chemotherapy

Volumn 23, Issue 3, 2013, Pages 77-91

  Cianci, Christopher ^a   Gerritz, Samuel W ^a   Deminie, Carol ^a   Krystal, Mark ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,3 DIHYDRO 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (2 FLUOROPHENYL)UREA; 1,2,4 TRIAZOLE DERIVATIVE; 3 MERCAPTO 1,2,4 TRIAZOLE DERIVATIVE; AMIDE; ANTIVIRUS AGENT; ARYL PIPERAZINE AMIDE DERIVATIVE; INFLUENZA VACCINE; MESSENGER RNA; NUCLEOZIN; PIPERAZINE DERIVATIVE; RSV 604T; UNCLASSIFIED DRUG; VIRUS NUCLEOPROTEIN; VIRUS RNA;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; DRUG PROTEIN BINDING; HUMAN; INFLUENZA; MOUSE MODEL; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TARGETING; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; RNA REPLICATION; RNA TRANSCRIPTION; VIRUS NUCLEOCAPSID;

AMIDES; ANIMALS; ANTIVIRAL AGENTS; DRUG DISCOVERY; HUMANS; INFLUENZA, HUMAN; INFLUENZAVIRUS A; MODELS, MOLECULAR; MOLECULAR TARGETED THERAPY; NUCLEOPROTEINS; ORTHOMYXOVIRIDAE INFECTIONS; PIPERAZINES; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 84875762843     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP2235     Document Type: Review

References (148)

1. WHO. Influenza fact sheet 211. (Updated April 2009. Accessed 7 January 2013.) Available from http://www.who.int/mediacentre/factsheets/fs211/en/
2. Taubenberger JK, Morens DM. Influenza revisited. Emerg Infect Dis 2006; 12:1-2.
3. Subbarao K, Klimov A, Katz J, et al. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 1998; 279:393-396.
4. Suarez DL, Perdue ML, Cox N, et al. Comparisons of highly virulent H5N1 influenza A viruses isolated from humans and chickens from Hong Kong. J Virol 1998; 72:6678-6688.
5. Webster RG. Influenza virus: transmission between species and relevance to emergence of the next human pandemic. Arch Virol Suppl 1997; 13:105-113.
6. Trampuz A, Prabhu RM, Smith TF, Baddour LM. Avian influenza: a new pandemic threat? Mayo Clin Proc 2004; 79:523-530.
7. Hayden F. Developing new antiviral agents for influenza treatment: what does the future hold? Clin Infect Dis 2009; 48 Suppl 1:S3-S13.
8. Pinto LH, Holsinger LJ, Lamb RA. Influenza virus M2 protein has ion channel activity. Cell 1992; 69:517-528.
9. Wharton SA, Belshe RB, Skehel JJ, Hay AJ. Role of virion M2 protein in influenza virus uncoating: specific reduction in the rate of membrane fusion between virus and liposomes by amantadine. J Gen Virol 1994; 75:945-948.
10. Couch RB. A new antiviral agent for influenza - is there a clinical niche? N Engl J Med 1997; 337:927-928.
11. Hayden FG, Hoffman HE, Spyker DA. Differences in side effects of amantadine hydrochloride and rimantadine hydrochloride relate to differences in pharmacokinetics. Antimicrob Agents Chemother 1983; 23:458-464.
12. Hayden FG, Sperber SJ, Belshe RB, et al. Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine. Antimicrob Agents Chemother 1991; 35:1741-1747.
13. Hayden FG, Hay AJ. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr Top Microbiol Immunol 1992; 176:119-130.
14. Lan Y, Zhang Y, Dong L, et al. A comprehensive surveillance of adamantane resistance among human influenza A virus isolated from mainland China between 1956 and 2009. Antivir Ther 2010; 15:853-859.
15. Pabbaraju K, Wong S, Kits DK, Fox JD. Adamantane resistance in seasonal human influenza A viruses from Calgary, Alberta (January 2007 to August 2008). Can J Infect Dis Med Microbiol 2010; 21:e87-e91.
16. Burnet FM. Mucins and mucoids in relation to influenza virus action; the destruction of Francis inhibitor activity in a purifed mucoid by virus action. Aust J Exp Biol Med Sci 1948; 26:389-402.
17. Gottschalk A. The synthesis of 2-carboxypyrrole from d-glucosamine and pyruvic acid: its bearing on the structure of neuraminic acid. Arch Biochem Biophys 1957; 69:37-44.
18. Varghese JN, Laver WG, Colman PM. Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution. Nature 1983; 303:35-40.
19. Rott R, Klenk HD. Significance of viral glycoproteins for infectivity and pathogenicity. Zentralbl Bakteriol Mikrobiol Hyg [A] 1987; 266:145-154.
20. Varghese JN, McKimm-Breschkin JL, Caldwell JB, Kortt AA, Colman PM. The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins 1992; 14:327-332.
21. Ryan DM, Ticehurst J, Dempsey MH, Penn CR. Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase). Antimicrob Agents Chemother 1994; 38:2270-2275.
22. Ryan DM, Ticehurst J, Dempsey MH. GG-167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is a potent inhibitor of influenza virus in ferrets. Antimicrob Agents Chemother 1995; 39:2583-2584.
23. Hayden FG, Osterhaus AD, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. N Engl J Med 1997; 337:874-880.
24. Hayden FG, Gubareva LV, Monto AS, et al. Inhaled zanamivir for the prevention of influenza in families. N Engl J Med 2000; 343:1282-1289.
25. Eisenberg EJ, Bidgood A, Cundy KC. Penetration of GS4071, a novel influenza neuraminidase inhibitor, into rat bronchoalveolar lining fluid following oral administration of the prodrug GS4104. Antimicrob Agents Chemother 1997; 41:1949-1952.
26. Li W, Escarpe PA, Eisenberg EJ, et al. Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother 1998; 42:647-653.
27. Ciancio BC, Meerhoff TJ, Kramarz P, et al. Oseltamivir-resistant influenza A(H1N1) viruses detected in Europe during season 2007-8 had epidemiologic and clinical characteristics similar to co-circulating susceptible A(H1N1) viruses. Euro Surveill 2009; 14:19412.
28. Myers JL, Hensley SE. Oseltamivir-resistant influenza viruses get by with a little help from permissive mutations. Expert Rev Anti Infect Ther 2011; 9:385-388.
29. Normile D, Enserink M. Avian influenza. With change in the seasons, bird fu returns. Science 2007; 315:448.
30. Leung YH, Lim WL, Wong MH, Chuang SK. Delayed oseltamivir treatment is associated with longer viral shedding of pandemic (H1N1) 2009 virus. Epidemiol Infect 2012; 140:814-817.
31. Meijer A, Jonges M, Abbink F, et al. Oseltamivir-resistant pandemic A(H1N1) 2009 influenza viruses detected through enhanced surveillance in the Netherlands, 2009-2010. Antiviral Res 2011; 92:81-89.
32. Krystal MR, Meanwell NA. Influenza--the case for combination therapy. Curr Opin Investig Drugs 2009; 10:746-749.
33. Smee DF, Hurst BL, Wong MH, Bailey KW, Morrey JD. Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice. Antimicrob Agents Chemother 2009; 53:2120-2128.
34. Bantia S, Kellogg D, Parker CD, Babu YS. Combination of peramivir and rimantadine demonstrate synergistic antiviral effects in sub-lethal influenza A (H3N2) virus mouse model. Antiviral Res 2010; 88:276-280.
35. Smee DF, Hurst BL, Wong MH, et al. Combinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice. Antiviral Res 2010; 88:38-44.
36. Kim WY, Young Suh G, Huh JW, et al. Triple-combination antiviral drug for pandemic H1N1 influenza virus infection in critically Ill patients on mechanical ventilation. Antimicrob Agents Chemother 2011; 55:5703-5709.
37. Kao RY, Yang D, Lau LS, et al. Identification of influenza A nucleoprotein as an antiviral target. Nat Biotechnol 2010; 28:600-605.
38. Su CY, Cheng TJ, Lin MI, et al. High-throughput identification of compounds targeting influenza RNA-dependent RNA polymerase activity. Proc Natl Acad Sci U S A 2010; 107:19151-19156.
39. Gerritz SW, Cianci C, Kim S, et al. Inhibition of influenza virus replication via small molecules that induce the formation of higher-order nucleoprotein oligomers. Proc Natl Acad Sci U S A 2011; 108:15366-15371.
40. Cheng H, Wan J, Lin MI, et al. Design, synthesis, and in vitro biological evaluation of 1H-1,2,3-triazole-4-carboxamide derivatives as new anti-influenza A agents targeting virus nucleoprotein. J Med Chem 2012; 55:2144-2153.
41. Ruigrok RWH, Crepin T. Nucleoproteins of negative strand RNA viruses; RNA binding, oligomerisation and binding to polymerase co-factor. Viruses 2010; 2:27-32.
42. Krug RM, Alonso-Caplen FV, Julkunen I, Katze MG. Expression and replication of the influenza virus genome. New York, NY: Plenum Press 1989. pp. 89-152.
43. Ritchey MB, Palese P, Kilbourne ED. RNAs of influenza A, B, and C viruses. J Virol 1976; 18:738-744.
44. Huang TS, Palese P, Krystal M. Determination of influenza virus proteins required for genome replication. J Virol 1990; 64:5669-5673.
45. Li ML, Ramirez BC, Krug RM. RNA-dependent activation of primer RNA production by influenza virus polymerase: different regions of the same protein subunit constitute the two required RNA-binding sites. EMBO J 1998; 17:5844-5852.
46. Duesberg PH. Distinct subunits of the ribonucleoprotein of influenza virus. J Mol Biol 1969; 42:485-499.
47. Compans RW, Content J, Duesberg PH. Structure of the ribonucleoprotein of influenza virus. J Virol 1972; 10:795-800.
48. Van Rompuy L, Min Jou W, Huylebroeck D, Devos R, Fiers W. Complete nucleotide sequence of the nucleoprotein gene from the human influenza strain A/PR/8/34 (HON1). Eur J Biochem 1981; 116:347-353.
49. Prokudina EN, Semenova NP, Chumakov VM. Stability of intracellular influenza virus nucleocapsid protein oligomers. Arch Virol 2005; 150:833-839.
50. Baudin F, Bach C, Cusack S, Ruigrok RW. Structure of influenza virus RNP. I. Influenza virus nucleoprotein melts secondary structure in panhandle RNA and exposes the bases to the solvent. EMBO J 1994; 13:3158-3165.
51. Ortega J, Martin-Benito J, Zurcher T, et al. Ultrastructural and functional analyses of recombinant influenza virus ribonucleoproteins suggest dimerization of nucleoprotein during virus amplification. J Virol 2000; 74:156-163.
52. Klumpp K, Ruigrok RW, Baudin F. Roles of the influenza virus polymerase and nucleoprotein in forming a functional RNP structure. EMBO J 1997; 16:1248-1257.
53. Noda T, Sagara H, Yen A, et al. Architecture of ribonucleoprotein complexes in influenza A virus particles. Nature 2006; 439:490-492.
54. Chou YY, Vafabakhsh R, Doganay S, et al. One influenza virus particle packages eight unique viral RNAs as shown by FISH analysis. Proc Natl Acad Sci U S A 2012; 109:9101-9106.
55. Ruigrok RW, Baudin F. Structure of influenza virus ribonucleoprotein particles. II. Purifed RNA-free influenza virus ribonucleoprotein forms structures that are indistinguishable from the intact influenza virus ribonucleoprotein particles. J Gen Virol 1995; 76:1009-1014.
56. Pons MW, Schulze IT, Hirst GK, Hauser R. Isolation and characterization of the ribonucleoprotein of influenza virus. Virology 1969; 39:250-259.
57. Ye Q, Krug RM, Tao YJ. The mechanism by which influenza A virus nucleoprotein forms oligomers and binds RNA. Nature 2006; 444:1078-1082.
58. Ng AK, Zhang H, Tan K, et al. Structure of the influenza virus A H5N1 nucleoprotein: implications for RNA binding, oligomerization, and vaccine design. FASEB J 2008; 22:3638-3647.
59. Elton D, Medcalf L, Bishop K, Harrison D, Digard P. Identification of amino acid residues of influenza virus nucleoprotein essential for RNA binding. J Virol 1999; 73:7357-7367.
60. Shen YF, Chen YH, Chu SY, et al. E339...R416 salt bridge of nucleoprotein as a feasible target for influenza virus inhibitors. Proc Natl Acad Sci U S A 2011; 108:16515-16520.
61. Martín-Benito J, Area E, Ortega J, et al. Three-dimensional reconstruction of a recombinant influenza virus ribonucleoprotein particle. EMBO Rep 2001; 2:313-317.
62. Area E, Martin-Benito J, Gastaminza P, et al. 3D structure of the influenza virus polymerase complex: Localization of subunit domains. Proc Natl Acad Sci U S A 2004; 101:308-313.
63. Coloma R, Valpuesta JM, Arranz R, et al. The structure of a biologically active influenza virus ribonucleoprotein complex. PLoS Pathog 2009; 5:e1000491.
64. Medcalf L, Poole E, Elton D, Digard P. Temperature-sensitive lesions in two influenza A viruses defective for replicative transcription disrupt RNA binding by the nucleoprotein. J Virol 1999; 73:7349-7356.
65. Poole E, Elton D, Medcalf L, Digard P. Functional domains of the influenza A virus PB2 protein: identification of NP-and PB1-binding sites. Virology 2004; 321:120-133.
66. Biswas SK, Boutz PL, Nayak DP. Influenza virus nucleoprotein interacts with influenza virus polymerase proteins. J Virol 1998; 72:5493-5501.
67. Martin K, Helenius A. Transport of incoming influenza virus nucleocapsids into the nucleus. J Virol 1991; 65:232-244.
68. O'Neill RE, Jaskunas R, Blobel G, Palese P, Moroianu J. Nuclear import of influenza virus RNA can be mediated by viral nucleoprotein and transport factors required for protein import. J Biol Chem 1995; 270:22701-22704.
69. Avalos RT, Yu Z, Nayak DP. Association of influenza virus NP and M1 proteins with cellular cytoskeletal elements in influenza virus-infected cells. J Virol 1997; 71:2947-2958.
70. Digard P, Elton D, Bishop K, et al. Modulation of nuclear localization of the influenza virus nucleoprotein through interaction with actin flaments. J Virol 1999; 73:2222-2231.
71. Herz C, Stavnezer E, Krug R, Gurney T, Jr. Influenza virus, an RNA virus, synthesizes its messenger RNA in the nucleus of infected cells. Cell 1981; 26:391-400.
72. Jackson DA, Caton AJ, McCready SJ, Cook PR. Influenza virus RNA is synthesized at fxed sites in the nucleus. Nature 1982; 296:366-368.
73. Paine PL, Moore LC, Horowitz SB. Nuclear envelope permeability. Nature 1975; 254:109-114.
74. Wang P, Palese P, O'Neill RE. The NPI-1/NPI-3 (karyopherin alpha) binding site on the influenza a virus nucleoprotein NP is a nonconventional nuclear localization signal. J Virol 1997; 71:1850-1856.
75. Weber F, Kochs G, Gruber S, Haller O. A classical bipartite nuclear localization signal on Thogoto and influenza A virus nucleoproteins. Virology 1998; 250:9-18.
76. Bullido R, Gomez-Puertas P, Albo C, Portela A. Several protein regions contribute to determine the nuclear and cytoplasmic localization of the influenza A virus nucleoprotein. J Gen Virol 2000; 81:135-142.
77. Cros J F, Garcia-Sastre A, Palese P. An unconventional NLS is critical for the nuclear import of the influenza A virus nucleoprotein and ribonucleoprotein. Traffic 2005; 6:205-213.
78. Görlich D, Kutay U. Transport between the cell nucleus and the cytoplasm. Annu Rev Cell Dev Biol 1999; 15:607-660.
79. Neumann G, Castrucci MR, Kawaoka Y. Nuclear import and export of influenza virus nucleoprotein. J Virol 1997; 71:9690-9700.
80. Davey J, Dimmock NJ, Colman A. Identification of the sequence responsible for the nuclear accumulation of the influenza virus nucleoprotein in Xenopus oocytes. Cell 1985; 40:667-675.
81. Martin K, Helenius A. Nuclear transport of influenza virus ribonucleoproteins: the viral matrix protein (M1) promotes export and inhibits import. Cell 1991; 67:117-130.
82. Bui M, Myers JE, Whittaker GR. Nucleo-cytoplasmic localization of influenza virus nucleoprotein depends on cell density and phosphorylation. Virus Res 2002; 84:37-44.
83. Sakaguchi A, Hirayama E, Hiraki A, Ishida Y, Kim J. Nuclear export of influenza viral ribonucleoprotein is temperature-dependently inhibited by dissociation of viral matrix protein. Virology 2003; 306:244-253.
84. Hirayama E, Atagi H, Hiraki A, Kim J. Heat shock protein 70 is related to thermal inhibition of nuclear export of the influenza virus ribonucleoprotein complex. J Virol 2004; 78:1263-1270.
85. Dalton RM, Mullin AE, Amorim MJ, et al. Temperature sensitive influenza A virus genome replication results from low thermal stability of polymerase-cRNA complexes. Virol J 2006; 3:58.
86. Ma K, Roy AM, Whittaker GR. Nuclear export of influenza virus ribonucleoproteins: identification of an export intermediate at the nuclear periphery. Virology 2001; 282:215-220.
87. Watanabe K, Takizawa N, Katoh M, et al. Inhibition of nuclear export of ribonucleoprotein complexes of influenza virus by leptomycin B. Virus Res 2001; 77:31-42.
88. Elton D, Simpson-Holley M, Archer K, et al. Interaction of the influenza virus nucleoprotein with the cellular CRM1-mediated nuclear export pathway. J Virol 2001; 75:408-419.
89. Kudo N, Wolff B, Sekimoto T, et al. Leptomycin B inhibition of signal-mediated nuclear export by direct binding to CRM1. Exp Cell Res 1998; 242:540-547.
90. Yu M, Liu X, Cao S, et al. Identification and characterization of three novel nuclear export signals in the influenza A virus nucleoprotein. J Virol 2012; 86:4970-4980.
91. Neumann G, Hughes MT, Kawaoka Y. Influenza A virus NS2 protein mediates vRNP nuclear export through NES-independent interaction with hCRM1. EMBO J 2000; 19:6751-6758.
92. Huang X, Liu T, Muller J, Levandowski RA, Ye Z. Effect of influenza virus matrix protein and viral RNA on ribonucleoprotein formation and nuclear export. Virology 2001; 287:405-416.
93. Akarsu H, Burmeister WP, Petosa C, et al. Crystal structure of the M1 protein-binding domain of the influenza A virus nuclear export protein (NEP/NS2). EMBO J 2003; 22:4646-4655.
94. Chase GP, Rameix-Welti MA, Zvirbliene A, et al. Influenza virus ribonucleoprotein complexes gain preferential access to cellular export machinery through chromatin targeting. PLoS Pathog 2011; 7:e1002187.
95. Roberts PC, Compans RW. Host cell dependence of viral morphology. Proc Natl Acad Sci U S A 1998; 95:5746-5751.
96. Husain M, Gupta CM. Interactions of viral matrix protein and nucleoprotein with the host cell cytoskeletal actin in influenza viral infection. Curr Sci 1997; 73:40-47.
97. Simpson-Holley M, Ellis D, Fisher D, et al. A functional link between the actin cytoskeleton and lipid rafts during budding of flamentous influenza virions. Virology 2002; 301:212-225.
98. Amorim MJ, Bruce EA, Read EK, et al. A Rab11- and microtubule-dependent mechanism for cytoplasmic transport of influenza A virus viral RNA. J Virol 2011; 85:4143-4156.
99. Eisfeld AJ, Kawakami E, Watanabe T, Neumann G, Kawaoka Y. RAB11A is essential for transport of the influenza virus genome to the plasma membrane. J Virol 2011; 85:6117-6126.
100. Momose F, Sekimoto T, Ohkura T, et al. Apical transport of influenza A virus ribonucleoprotein requires Rab11-positive recycling endosome. PLoS ONE 2011; 6:e21123.
101. Barry RD, Mahy BW. The influenza virus genome and its replication. Br Med Bull 1979; 35:39-46.
102. Mahy BW, Carroll AR, Brownson JM, McGeoch DJ. Block to influenza virus replication in cells preirradiated with ultraviolet light. Virology 1977; 83:150-162.
103. Krug RM, Broni BA, Bouloy M. Are the 5′ ends of influenza viral mRNAs synthesized in vivo donated by host mRNAs? Cell 1979; 18:329-334.
104. Plotch SJ, Bouloy M, Ulmanen I, Krug RM. A unique cap(m7GpppXm)-dependent influenza virion endonuclease cleaves capped RNAs to generate the primers that initiate viral RNA transcription. Cell 1981; 23:847-858.
105. Braam J, Ulmanen I, Krug RM. Molecular model of a eucaryotic transcription complex: functions and movements of influenza P proteins during capped RNA-primed transcription. Cell 1983; 34:609-618.
106. Ulmanen I, Broni BA, Krug RM. Role of two of the influenza virus core P proteins in recognizing cap 1 structures (m7GpppNm) on RNAs and in initiating viral RNA transcription. Proc Natl Acad Sci U S A 1981; 78:7355-7359.
107. Blaas D, Patzelt E, Kuechler E. Identification of the cap binding protein of influenza virus. Nucleic Acids Res 1982; 10:4803-4812.
108. Hara K, Schmidt FI, Crow M, Brownlee GG. Amino acid residues in the N-terminal region of the PA subunit of influenza A virus RNA polymerase play a critical role in protein stability, endonuclease activity, cap binding, and virion RNA promoter binding. J Virol 2006; 80:7789-7798.
109. Dias A, Bouvier D, Crepin T, et al. The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit. Nature 2009; 458:914-918.
110. Yuan P, Bartlam M, Lou Z, et al. Crystal structure of an avian influenza polymerase PA(N) reveals an endonuclease active site. Nature 2009; 458:909-913.
111. Tiley LS, Hagen M, Matthews JT, Krystal M. Sequence-specific binding of the influenza virus RNA polymerase to sequences located at the 5' ends of the viral RNAs. J Virol 1994; 68:5108-5116.
112. Fodor E, Pritlove DC, Brownlee GG. The influenza virus panhandle is involved in the initiation of transcription. J Virol 1994; 68:4092-4096.
113. Plotch SJ, Krug RM. Influenza virion transcriptase: synthesis in vitro of large, polyadenylic acid-containing complementary RNA. J Virol 1977; 21:24-34.
114. Hay AJ, Abraham G, Skehel JJ, Smith JC, Fellner P. Influenza virus messenger RNAs are incomplete transcripts of the genome RNAs. Nucleic Acids Res 1977; 4:4197-4209.
115. Robertson JS, Schubert M, Lazzarini RA. Polyadenylation sites for influenza virus mRNA. J Virol 1981; 38:157-163.
116. Li X, Palese P. Characterization of the polyadenylation signal of influenza virus RNA. J Virol 1994; 68:1245-1249.
117. Poon LLM, Pritlove DC, Fodor E, Brownlee GG. Direct evidence that the Poly(A) tail of influenza A virus mRNA is synthesized by reiterative copying of a U track in the virion RNA template. J Virol 1999; 73:3473-3476.
118. Young RJ, Content J. 5′-Terminus of influenza virus RNA. Nat New Biol 1971; 230:140-142.
119. Barrett T, Wolstenholme AJ, Mahy B W. Transcription and replication of influenza virus RNA. Virology 1979; 98:211-225.
120. Hay AJ, Lomniczi B, Bellamy AR, Skehel JJ. Transcription of the influenza virus genome. Virology 1977; 83:337-355.
121. Hay AJ, Skehel JJ, McCauley J. Characterization of influenza virus RNA complete transcripts. Virology 1982; 116:517-522.
122. Honda A, Ueda K, Nagata K, Ishihama A. RNA polymerase of influenza virus: role of NP in RNA chain elongation. J Biochem 1988; 104:1021-1026.
123. Lee MT, Bishop K, Medcalf L, et al. Defnition of the minimal viral components required for the initiation of unprimed RNA synthesis by influenza virus RNA polymerase. Nucleic Acids Res 2002; 30:429-438.
124. Beaton AR, Krug RM. Transcription antitermination during influenza viral template RNA synthesis requires the nucleocapsid protein and the absence of a 5′ capped end. Proc Natl Acad Sci U S A 1986; 83:6282-6286.
125. Shapiro GI, Krug RM. Influenza virus RNA replication in vitro: synthesis of viral template RNAs and virion RNAs in the absence of an added primer. J Virol 1988; 62:2285-2290.
126. Krug RM, Ueda M, Palese P. Temperature-sensitive mutants of influenza WSN virus defective in virus-specific RNA synthesis. J Virol 1975; 16:790-796.
127. Mena I, Jambrina E, Albo C, et al. Mutational analysis of influenza A virus nucleoprotein: identification of mutations that affect RNA replication. J Virol 1999; 73:1186-1194.
128. Resa-Infante P, Jorba N, Coloma R, Ortin J. The influenza virus RNA synthesis machine: Advances in its structure and function. RNA Biol 2011; 8:207-215.
129. Vreede FT, Brownlee GG. Influenza virion-derived viral ribonucleoproteins synthesize both mRNA and cRNA in vitro. J Virol 2007; 81:2196-2204.
130. Olson AC, Rosenblum E, Kuchta RD. Regulation of influenza RNA polymerase activity and the switch between replication and transcription by the concentrations of the vRNA 5′ end, the cap source, and the polymerase. Biochemistry 2010; 49:10208-10215.
131. Townsend AR, Skehel JJ. The influenza A virus nucleoprotein gene controls the induction of both subtype specific and cross-reactive cytotoxic T cells. J Exp Med 1984; 160:552-563.
132. Yewdell JW, Bennink JR, Smith GL, Moss B. Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc Natl Acad Sci U S A 1985; 82:1785-1789.
133. Gorman OT, Bean WJ, Kawaoka Y, Webster RG. Evolution of the nucleoprotein gene of influenza A virus. J Virol 1990; 64:1487-1497.
134. Shu LL, Bean WJ, Webster RG. Analysis of the evolution and variation of the human influenza A virus nucleoprotein gene from 1933 to 1990. J Virol 1993; 67:2723-2729.
135. Hillaire ML, Osterhaus AD, Rimmelzwaan GF. Induction of virus-specific cytotoxic T lymphocytes as a basis for the development of broadly protective influenza vaccines. J Biomed Biotechnol 2011; 2011:939860.
136. Durando P, Iudici R, Alicino C, et al. Aduvants and alternative routes of administration towards the development of the ideal influenza vaccine. Hum Vaccin 2011; 7 Suppl:29-40.
137. Cox MM. Cell-based protein vaccines for influenza. Curr Opin Mol Ther 2005; 7:24-29.
138. Cox MM. Progress on baculovirus-derived influenza vaccines. Curr Opin Mol Ther 2008; 10:56-61.
139. Roose K, Fiers W, Saelens X. Pandemic preparedness: toward a universal influenza vaccine. Drug News Perspect 2009; 22:80-92.
140. Ng AK, Lam MK, Zhang H, et al. Structural basis for RNA-binding and homo-oligomer formation by influenza B virus nucleoprotein. J Virol 2012; 86:6758-6767.
141. Jiang H, Xu Y, Li L, et al. Inhibition of influenza virus replication by constrained peptides targeting nucleoprotein. Antivir Chem Chemother 2011; 22:119-130.
142. Fedichev P, Timakhov R, Pyrkov T, Getmantsev E, Vinnik A. Structure-based drug design of a new chemical class of small molecules active against influenza A nucleoprotein in vitro and in vivo. PLoS Curr 2011; 3:RRN1253.
143. Hagiwara K, Kondoh Y, Ueda A, et al. Discovery of novel antiviral agents directed against the influenza A virus nucleoprotein using photo-cross-linked chemical arrays. Biochem Biophys Res Commun 2010; 394:721-727.
144. Chapman J, Abbott E, Alber DG, et al. RSV604, a novel inhibitor of respiratory syncytial virus replication. Antimicrob Agents Chemother 2007; 51:3346-3353.
145. Henderson EA, Alber DG, Baxter RC, et al. 1,4-Benzodiazepines as inhibitors of respiratory syncytial virus. The Identification of a Clinical Candidate. J Med Chem 2007; 50:1685-1692.
146. Tawar RG, Duquerroy S, Vonrhein C, et al. Crystal structure of a nucleocapsid-like nucleoprotein-RNA complex of respiratory syncytial virus. Science 2009; 326:1279-1283.
147. Jefferson T, Di Pietrantonj C, Rivetti A, et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2010; CD001269.
148. Jefferson T, Jones M, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: a Cochrane review. Health Technol Assess 2010; 14:355-458.